RxDoctor Payments DataLook up a doctor →

Gregory Rau

Medical · New Haven, CTNPI 1528006038

Payments from drug & device makers

$211,289in general payments, 2019–2025

Across 1,009 payments — averaging $209.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$60K
  • AbbVie$59K
  • Amgen$38K
  • LEO Pharma Inc.$28K
  • Pfizer$15K
  • Galderma Laboratories, L.p.$6K
  • plus $6K from 20 others

What the payments were for

  • Consulting fees$10,2455%
  • Speaking & faculty fees$168,26780%
  • Travel & lodging$16,5018%
  • Food & beverage$16,2498%
  • Education$280%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$211,289 in reported general payments places this provider in the 95th percentile of 592 medical providers in Connecticut.

See all medical providers in Connecticut

Medicare billing

Part B allowed, 2024
$122,743
Medicare patients
669
Services billed
1,844

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab17$197,321
OtezlaApremilast25$122,334
Dupixent PenDupilumab22$97,098
Dupixent SyringeDupilumab14$61,809
Fluorouracil100$6,814
Doxycycline Hyclate83$2,219
Metronidazole42$2,065
Ketoconazole111$2,012
Clobetasol Propionate43$1,875
Clindamycin Phosphate37$1,564
Triamcinolone Acetonide137$1,555
Tretinoin12$1,257
Minocycline Hcl25$1,230
Betamethasone Diprop AugmentedBetamethasone/Propylene Glyc44$768
Fluocinonide30$767

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenOtezla$37,516$122,33425 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 592 medical providers in Connecticut.

Other medical in New Haven

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →